DE60335731D1 - Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer - Google Patents
Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmerInfo
- Publication number
- DE60335731D1 DE60335731D1 DE60335731T DE60335731T DE60335731D1 DE 60335731 D1 DE60335731 D1 DE 60335731D1 DE 60335731 T DE60335731 T DE 60335731T DE 60335731 T DE60335731 T DE 60335731T DE 60335731 D1 DE60335731 D1 DE 60335731D1
- Authority
- DE
- Germany
- Prior art keywords
- sulfamates
- sulfamides
- sulphonamides
- gamma secretase
- secretase inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003540 gamma secretase inhibitor Substances 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0225474.6A GB0225474D0 (en) | 2002-11-01 | 2002-11-01 | Therapeutic agents |
| PCT/GB2003/004707 WO2004039370A1 (en) | 2002-11-01 | 2003-10-29 | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60335731D1 true DE60335731D1 (de) | 2011-02-24 |
Family
ID=9947009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60335731T Expired - Lifetime DE60335731D1 (de) | 2002-11-01 | 2003-10-29 | Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7144910B2 (de) |
| EP (1) | EP1560580B1 (de) |
| JP (1) | JP4536517B2 (de) |
| AT (1) | ATE494893T1 (de) |
| AU (1) | AU2003276435B2 (de) |
| CA (1) | CA2503868C (de) |
| DE (1) | DE60335731D1 (de) |
| GB (1) | GB0225474D0 (de) |
| WO (1) | WO2004039370A1 (de) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001240861B2 (en) * | 2000-03-20 | 2006-03-30 | Merck Frosst Canada Ltd | Sulphonamido-substituted bridged bicycloalkyl derivatives |
| KR100927304B1 (ko) | 2001-12-27 | 2009-11-18 | 다이이찌 세이야꾸 가부시기가이샤 | β-아밀로이드 단백 생산·분비 저해제 |
| GB0308318D0 (en) | 2003-04-10 | 2003-05-14 | Merck Sharp & Dohme | Therapeutic agents |
| MXPA05013631A (es) | 2003-06-30 | 2006-02-24 | Daiichi Seiyaku Co | Derivado heterociclico de metilsulfona. |
| WO2005030731A1 (en) * | 2003-09-24 | 2005-04-07 | Merck Sharp & Dohme Limited | Gamma-secretase inhibitors |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| CA2644136A1 (en) | 2006-02-27 | 2007-09-07 | The Johns Hopkins University | Cancer treatment with gamma-secretase inhibitors |
| EP2089383B1 (de) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydroxy-1,5-dihydropyrrol-2-one derivate als inhibitoren von glutaminylcyclase zur behandlung von geschwüren, krebs und anderen krankheiten |
| CA2669693C (en) | 2006-11-15 | 2018-06-12 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2009035522A1 (en) * | 2007-09-14 | 2009-03-19 | Albert Einstein College Of Medicine Of Yeshiva University | Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease |
| US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| RU2531915C2 (ru) * | 2008-06-09 | 2014-10-27 | Людвиг-Максимилианс-Универзитет Мюнхен | Новые лекарственные средства для ингибирования агрегации белков, вовлеченных в заболевания, связанные с агрегацией белков, и нейродегенеративные заболевания |
| US10143711B2 (en) | 2008-11-24 | 2018-12-04 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| MX2012004377A (es) | 2009-10-14 | 2012-06-01 | Merck Sharp & Dohme | Piperidinas sustituidas que aumentan la actividad de p53 y sus usos. |
| WO2011046774A1 (en) * | 2009-10-16 | 2011-04-21 | Merck Sharp & Dohme Corp. | Diaryl ether derivatives as notch sparing gamma secretase inhibitors |
| US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP2584903B1 (de) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Neue heterozyklische verbindungen als erk-hemmer |
| EP2601293B1 (de) | 2010-08-02 | 2017-12-06 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina) |
| AU2011292261B2 (en) | 2010-08-17 | 2015-05-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| EP2613782B1 (de) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| EP2615916B1 (de) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Kondensierte pyrazolderivate als neue erk-hemmer |
| EP3327125B1 (de) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2686313B1 (de) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazolderivate als glutaminylcyclase-hemmer |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP3453762B1 (de) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| WO2014039781A1 (en) | 2012-09-07 | 2014-03-13 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| MX2015004041A (es) | 2012-09-28 | 2015-07-06 | Merck Sharp & Dohme | Compuestos novedosos que son inhibidores de erk. |
| RU2660349C2 (ru) | 2012-11-28 | 2018-07-05 | Мерк Шарп И Доум Корп. | Композиции и способы для лечения злокачественной опухоли |
| US8846657B2 (en) | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| EP2951180B1 (de) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8-substituierte purine als hdm2-inhibitoren |
| US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| CN106488775A (zh) | 2014-07-11 | 2017-03-08 | 基因泰克公司 | Notch途径抑制 |
| US20170314027A1 (en) | 2014-08-06 | 2017-11-02 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| SG10201913841SA (en) | 2015-07-24 | 2020-03-30 | Oncotracker Inc | Gamma secretase modulators for the treatment of immune system dysfunction |
| US11185536B2 (en) | 2015-12-04 | 2021-11-30 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
| CA3013038A1 (en) | 2016-01-29 | 2017-08-03 | Massachusetts Eye And Ear Infirmary | Expansion and differentiation of inner ear supporting cells and methods of use thereof |
| EP3458076A4 (de) | 2016-05-16 | 2020-01-22 | The General Hospital Corporation | Menschliche atemwegsstammzellen bei der züchtung von lungenepithel |
| RU2757276C2 (ru) | 2016-12-16 | 2021-10-12 | Пайплайн Терапьютикс, Инк. | Способы лечения кохлеарной синаптопатии |
| EP3582782B1 (de) | 2017-02-17 | 2023-06-07 | Fred Hutchinson Cancer Center | Kombinationstherapien zur behandlung von bcma-bedingten krebsarten und autoimmunerkrankungen |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| EP3706742B1 (de) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP4077282A4 (de) | 2019-12-17 | 2023-11-08 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| KR20230005163A (ko) | 2020-03-26 | 2023-01-09 | 씨젠 인크. | 다발성 골수종 치료 방법 |
| WO2024049931A1 (en) | 2022-09-02 | 2024-03-07 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
| WO2024091437A1 (en) | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001240861B2 (en) * | 2000-03-20 | 2006-03-30 | Merck Frosst Canada Ltd | Sulphonamido-substituted bridged bicycloalkyl derivatives |
| US7138400B2 (en) * | 2000-11-02 | 2006-11-21 | Merck Sharp & Dohme Limited | Sulfamides as gamma-secretase inhibitors |
-
2002
- 2002-11-01 GB GBGB0225474.6A patent/GB0225474D0/en not_active Ceased
-
2003
- 2003-10-29 WO PCT/GB2003/004707 patent/WO2004039370A1/en active Application Filing
- 2003-10-29 EP EP03809792A patent/EP1560580B1/de not_active Expired - Lifetime
- 2003-10-29 CA CA2503868A patent/CA2503868C/en not_active Expired - Fee Related
- 2003-10-29 AT AT03809792T patent/ATE494893T1/de not_active IP Right Cessation
- 2003-10-29 US US10/533,151 patent/US7144910B2/en not_active Expired - Fee Related
- 2003-10-29 JP JP2004547808A patent/JP4536517B2/ja not_active Expired - Fee Related
- 2003-10-29 AU AU2003276435A patent/AU2003276435B2/en not_active Ceased
- 2003-10-29 DE DE60335731T patent/DE60335731D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004039370A1 (en) | 2004-05-13 |
| JP2006506390A (ja) | 2006-02-23 |
| GB0225474D0 (en) | 2002-12-11 |
| AU2003276435A1 (en) | 2004-05-25 |
| CA2503868C (en) | 2011-09-20 |
| CA2503868A1 (en) | 2004-05-13 |
| EP1560580A1 (de) | 2005-08-10 |
| US20060069147A1 (en) | 2006-03-30 |
| US7144910B2 (en) | 2006-12-05 |
| AU2003276435B2 (en) | 2008-10-16 |
| ATE494893T1 (de) | 2011-01-15 |
| EP1560580B1 (de) | 2011-01-12 |
| JP4536517B2 (ja) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60335731D1 (de) | Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer | |
| ATE464287T1 (de) | Cyclohexyl-sulphone als gamma-sekretase- inhibitoren | |
| ATE302753T1 (de) | Sulfamide als gamma-secretase-inhibitoren | |
| DE60329533D1 (de) | Cyclische sulfamide zur inhibierung von gamma-sekretase | |
| ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
| MXPA05012323A (es) | Sulfonamidas ciclicas para la inhibicion de gama-secretasa. | |
| DE60328182D1 (de) | Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase | |
| DE60144064D1 (de) | Sulfone, die die aktivität von gamma-secretase modulieren | |
| ATE299890T1 (de) | Inhibitoren von gamma-secretase | |
| NO20005237D0 (no) | Heterocyklisk substituerte amider anvendt som calpain- inhibitorer | |
| ATE401314T1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| ATE354562T1 (de) | Cyclohexylsulfon-derivate als gamma-secretase- inhibitoren | |
| PE20071321A1 (es) | Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados | |
| DE60237725D1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
| ATE524452T1 (de) | Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen. | |
| MY149422A (en) | 5-(arylsulfonyl)-pyrazolopiperidines | |
| NO20062629L (no) | Oksazolderivater av tetrackliner | |
| BR0209149A (pt) | Ftalazinonas | |
| ATE416157T1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| DK1463735T3 (da) | Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider | |
| DOP2002000451A (es) | Nuevas ciclohexilsulfonas (agentes terapéuticos) | |
| NO20064793L (no) | Anvendelse av N-(2-arylpropionyl) sulfonamider for behandling av ryggmargskade. | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| GB0522908D0 (en) | Therapeutic agents | |
| ATE373637T1 (de) | N-(2-phenylethyl)sulfamid-derivate als integrin- alpha4-antagonisten |